Inhaled corticosteroids in COPD: friend or foe?

The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can result in clear clinical benefits in some patients (“friend”) but can be ineffective or even associated with undesired side effects, e.g. pneumonia, in others (“foe”). After critically reviewing the evidence for and against ICS treatment in patients with COPD, we propose that: 1) ICS should not be used as a single, stand-alone therapy in COPD; 2) patients most likely to benefit from the addition of ICS to long-acting bronchodilators include those with history of multiple or severe exacerbations despite appropriate maintenance bronchodilator use, particularly if blood eosinophils are >300 cells·µL−1, and those with a history of and/or concomitant asthma; and 3) the risk of pneumonia in COPD patients using ICS is higher in those with older age, lower body mass index (BMI), greater overall fragility, receiving higher ICS doses and those with blood eosinophils <100 cells·µL−1. All these factors must be carefully considered and balanced in any individual COPD patient before adding ICS to her/his maintenance bronchodilator treatment. Further research is needed to clarify some of these issues and firmly establish these recommendations. The use of inhaled corticosteroids in patients with COPD must be personalised http://ow.ly/ZyFI30lDfUR

[1]  E. Bateman,et al.  Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study , 2014, BMC Pulmonary Medicine.

[2]  Ciro Casanova,et al.  The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.

[3]  A. Anzueto,et al.  Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia , 2010, European Respiratory Journal.

[4]  J. Wedzicha,et al.  Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[5]  J. Wedzicha,et al.  Minimal clinically important differences in pharmacological trials. , 2014, American journal of respiratory and critical care medicine.

[6]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[7]  F. Blasi,et al.  Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease , 2015, Thorax.

[8]  R. Cumming,et al.  Use of inhaled and oral corticosteroids and the long-term risk of cataract. , 2009, Ophthalmology.

[9]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. , 2017, Respiratory medicine.

[10]  F. Martinez,et al.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.

[11]  F. Martinez,et al.  Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction , 2017, American journal of respiratory and critical care medicine.

[12]  A. Papi,et al.  Fluticasone propionate/formoterol for COPD management: a randomized controlled trial , 2017, International journal of chronic obstructive pulmonary disease.

[13]  D. Tashkin To Withdraw or Not to Withdraw Inhaled Corticosteroids from Triple Therapy in Chronic Obstructive Pulmonary Disease. , 2018, American journal of respiratory and critical care medicine.

[14]  C. Strange,et al.  Long-Term Effects of Inhaled Corticosteroids on FEV1 in Patients with Chronic Obstructive Pulmonary Disease , 2003, Annals of Internal Medicine.

[15]  D. Singh,et al.  Risk of pneumonia and exacerbations with single inhaler extrafine triple therapy compared to indacaterol/glycopyrronium: Post-hoc Analysis of the TRIBUTE Study , 2019, 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..

[16]  Yuejun Du,et al.  Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis , 2017, Inhalation toxicology.

[17]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.

[18]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[19]  S. Suissa,et al.  Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. , 2011, American journal of respiratory and critical care medicine.

[20]  C. Vogelmeier,et al.  “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD , 2017, International journal of chronic obstructive pulmonary disease.

[21]  H. Magnussen,et al.  Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD , 2015, European Respiratory Journal.

[22]  P. Calverley,et al.  Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. , 2014, Chest.

[23]  D. Postma,et al.  A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. , 2007, Chest.

[24]  F. Herth,et al.  Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease , 2014, Respiration.

[25]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[26]  Dave Singh,et al.  The reproducibility of COPD blood eosinophil counts , 2018, European Respiratory Journal.

[27]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[28]  K. Fong,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[29]  J. Drazen,et al.  Making Sense of Triple Inhaled Therapy for COPD. , 2018, The New England journal of medicine.

[30]  E. Wouters,et al.  Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. , 2017, American journal of respiratory and critical care medicine.

[31]  H. Magnussen,et al.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. , 2016, The Lancet. Respiratory medicine.

[32]  F. Martinez,et al.  Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk , 2018, American journal of respiratory and critical care medicine.

[33]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.

[34]  D. Price,et al.  Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. , 2016, Respiratory medicine.

[35]  P. Jones,et al.  Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. , 2014, Respiratory medicine.

[36]  B. Beghé,et al.  Inhaled corticosteroids in COPD: pros and cons. , 2013, Current drug targets.

[37]  L. Fabbri,et al.  Time for a longer and better life for patients with COPD , 2018, European Respiratory Journal.

[38]  J. Zhao,et al.  Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. , 2014, Journal of thoracic disease.

[39]  Dave Singh,et al.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.

[40]  M. Davoli,et al.  The Effect on Total Mortality of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy , 2016, COPD.

[41]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[42]  R. Barr,et al.  Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort , 2018 .

[43]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in COPD: the Copenhagen General Population Study. , 2015 .

[44]  Dave Singh,et al.  Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.

[45]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[46]  S. Rennard,et al.  Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire. , 2017, Chronic obstructive pulmonary diseases.

[47]  J. Wedzicha,et al.  Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial , 2007, Respiratory research.

[48]  Williams Mh,et al.  OBSTRUCTIVE PULMONARY DISEASE , 1964 .

[49]  S. Suissa Immeasurable time bias in observational studies of drug effects on mortality. , 2008, American journal of epidemiology.

[50]  J. Wedzicha,et al.  Long‐Term Triple Therapy De‐escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double‐Blind, Triple‐Dummy Clinical Trial , 2018, American journal of respiratory and critical care medicine.

[51]  D. Postma,et al.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial , 2005, Thorax.

[52]  E. Kerwin,et al.  Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial , 2012, International journal of chronic obstructive pulmonary disease.

[53]  S. Rennard,et al.  Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.

[54]  S. Rennard,et al.  Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease , 2009, Drugs.

[55]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[56]  A. Woodcock,et al.  Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability , 2018, European Respiratory Journal.

[57]  Sanjay Basu,et al.  Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials , 2017, PLoS medicine.

[58]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[59]  Kayleigh Kew,et al.  Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[60]  D. Postma,et al.  Relapse in FEV1 Decline After Steroid Withdrawal in COPD. , 2015, Chest.

[61]  B. Make,et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease. , 2007, Proceedings of the American Thoracic Society.

[62]  E. Ota,et al.  Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). , 2017, The Cochrane database of systematic reviews.

[63]  D. Postma,et al.  Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids , 2016, European Respiratory Journal.

[64]  M. Labrecque,et al.  Number of patients needed to prescribe statins in primary cardiovascular prevention: mirage and reality , 2018, Family practice.

[65]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.

[66]  Stephanie J. C. Taylor,et al.  Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology , 2011, Respiratory research.

[67]  J. Wedzicha,et al.  Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial , 2017, American journal of respiratory and critical care medicine.

[68]  T. To,et al.  Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. , 2014, JAMA.

[69]  Christine Jenkins,et al.  Health status in the TORCH study of COPD: treatment efficacy and other determinants of change , 2011, Respiratory research.

[70]  P. Calverley,et al.  Blood eosinophils as a marker of response to inhaled corticosteroids in COPD , 2016, European Respiratory Journal.

[71]  I. Pavord,et al.  Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.

[72]  M. Fine,et al.  Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. , 2011, American journal of respiratory and critical care medicine.

[73]  B. Beghé,et al.  Triple therapy for symptomatic patients with COPD , 2017, The Lancet.

[74]  N. Richard,et al.  Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. , 2014, Respiratory medicine.

[75]  J. Kwong,et al.  The risk of mycobacterial infections associated with inhaled corticosteroid use , 2017, European Respiratory Journal.

[76]  M. Decramer,et al.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.

[77]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[78]  Dirkje S Postma,et al.  The Asthma-COPD Overlap Syndrome. , 2015, The New England journal of medicine.

[79]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[80]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[81]  J. Wedzicha,et al.  An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. , 1999, Respiratory medicine.

[82]  A. Torres,et al.  New evidence of risk factors for community-acquired pneumonia: a population-based study , 2008, European Respiratory Journal.

[83]  D. Price,et al.  Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.

[84]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[85]  R. Holmes,et al.  Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.

[86]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[87]  R. Cavallazzi,et al.  Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies , 2011, Thorax.

[88]  T. Lasserson,et al.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.

[89]  J. Yim,et al.  Use of inhaled corticosteroids and the risk of tuberculosis , 2013, Thorax.

[90]  J. Wedzicha,et al.  Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[91]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[92]  J. Tu,et al.  Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[93]  E. R. Sutherland,et al.  Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis , 2003, Thorax.

[94]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[95]  N. Roche,et al.  Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.

[96]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[97]  J. Bourbeau,et al.  COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD , 2018, European Respiratory Journal.

[98]  L. Rose,et al.  Program of Integrated Care for Patients with Chronic Obstructive Pulmonary Disease and Multiple Comorbidities (PIC COPD+): a randomised controlled trial , 2018, European Respiratory Journal.

[99]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[100]  I. Pavord,et al.  Eosinophils in COPD: just another biomarker? , 2017, The Lancet. Respiratory medicine.

[101]  P. J. Barnes,et al.  Corticosteroid effects on cell signalling , 2006, European Respiratory Journal.

[102]  D. Witcher,et al.  A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia , 2012, Thorax.

[103]  B. Nordestgaard,et al.  Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD , 2018, European Respiratory Journal.

[104]  P. Kuna,et al.  Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. , 2010, Respiratory medicine.

[105]  M. Cazzola,et al.  Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. , 2017, Pulmonary pharmacology & therapeutics.

[106]  Pan‐Chyr Yang,et al.  Use of High-Dose Inhaled Corticosteroids is Associated With Pulmonary Tuberculosis in Patients With Chronic Obstructive Pulmonary Disease , 2010, Medicine.

[107]  J. Vestbo Triple-Therapie mit einem Inhalator , 2017, Pneumologie.

[108]  Meilan K. Han,et al.  Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort , 2017, The Lancet. Respiratory medicine.

[109]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[110]  A. Sharafkhaneh,et al.  Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.

[111]  Dave Singh,et al.  Inhaled corticosteroid containing combinations and mortality in COPD , 2018, European Respiratory Journal.

[112]  COPDGene Investigators,et al.  Blood eosinophil thresholds and exacerbations in chronic obstructive pulmonary disease , 2018 .

[113]  S. Suissa,et al.  Inhaled corticosteroids and the risks of diabetes onset and progression. , 2010, The American journal of medicine.

[114]  Dave Singh,et al.  Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. , 2017, The Journal of allergy and clinical immunology.

[115]  H. Neffen,et al.  A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD. , 2017, Pulmonary pharmacology & therapeutics.

[116]  F. Radner,et al.  Budesonide and the risk of pneumonia: a meta-analysis of individual patient data , 2009, The Lancet.

[117]  F. Martinez,et al.  Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. , 2018, American journal of respiratory and critical care medicine.

[118]  A. Agustí Filling the gaps in COPD: the TRIBUTE study , 2018, The Lancet.

[119]  D. Postma,et al.  Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity , 2013, Thorax.

[120]  Dave Singh,et al.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.

[121]  H. Sørensen,et al.  Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis , 2012, Thorax.

[122]  A. Anzueto,et al.  Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.

[123]  N. Pride,et al.  Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice , 2002, European Respiratory Journal.

[124]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[125]  N. Pride,et al.  Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. , 2005, American journal of respiratory and critical care medicine.

[126]  J. van der Palen,et al.  Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.

[127]  Pan‐Chyr Yang,et al.  Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia , 2014, Drug design, development and therapy.

[128]  C. Sherman,et al.  Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. , 2001, American journal of respiratory and critical care medicine.

[129]  A. Papi,et al.  INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD , 2014, European Respiratory Journal.

[130]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[131]  Alvar Agusti,et al.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.

[132]  D. Postma,et al.  A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. , 1992, The New England journal of medicine.

[133]  A. Anzueto,et al.  Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? , 2011, European Respiratory Journal.

[134]  P. Scanlon,et al.  Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? , 2015, American journal of respiratory and critical care medicine.

[135]  S. Suissa,et al.  Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.

[136]  K. Rabe Treating COPD--the TORCH trial, P values, and the Dodo. , 2007, The New England journal of medicine.

[137]  H. Magnussen,et al.  Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.

[138]  C. Nordeen Use of Inhaled Corticosteroids in Patients With COPD and the Risk of TB and Influenza: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2014 .

[139]  J. Soriano,et al.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.

[140]  S. Suissa,et al.  Observational Studies of Inhaled Corticosteroid Effectiveness in COPD: Lessons Learned , 2018, Chest.

[141]  I. Pavord,et al.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.

[142]  A. Akram,et al.  Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia , 2011, European Respiratory Journal.